Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis

被引：0
|
作者：
Chen, Lei [1 ]
Latremouille-Viau, Dominick [2 ]
Guerin, Annie [2 ]
Nitulescu, Roy [2 ]
Gagnon-Sanschagrin, Patrick [2 ]
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Anal Grp Inc, Montreal, PQ, Canada
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse
    Irish, William
    Ryan, Michael
    Gache, Larry
    Gunnarsson, Candace
    Bell, Timothy
    Shapiro, Mark
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (03) : 519 - 527
  • [32] TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION AND ASSOCIATED COSTS BY LINE OF THERAPY IN NEWLY DIAGNOSED MERKEL CELL CANCER PATIENTS IN THE UNITED STATES
    Kearney, M.
    Boutmy, E.
    Locker, M.
    Penalvo, J.
    Bharmal, M.
    VALUE IN HEALTH, 2018, 21 : S46 - S46
  • [33] Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis
    Gauthier, Genevieve
    Guerin, Annie
    Zhdanava, Maryia
    Jacobson, William
    Nomikos, George
    Merikle, Elizabeth
    Francois, Clement
    Perez, Vanessa
    BMC PSYCHIATRY, 2017, 17
  • [34] Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis
    Geneviève Gauthier
    Annie Guérin
    Maryia Zhdanava
    William Jacobson
    George Nomikos
    Elizabeth Merikle
    Clément François
    Vanessa Perez
    BMC Psychiatry, 17
  • [35] BUDGET IMPACT ANALYSIS OF NILOTINIB AS FIRST LINE TREATMENT OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) WITH HIGH RISK SOKAL SCORE IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
    Kim, H. S. J.
    Buehler, A.
    Matsuo, A. L.
    VALUE IN HEALTH, 2019, 22 : S462 - S462
  • [36] Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
    Massimo Breccia
    Giuliana Alimena
    BioDrugs, 2011, 25 : 147 - 157
  • [37] Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: A network meta-analysis
    Signorovitch, James
    Ayyagari, Rajeev
    Reichmann, William M.
    Wu, Eric Q.
    Chen, Lei
    CANCER TREATMENT REVIEWS, 2014, 40 (02) : 285 - 292
  • [38] An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
    Luis Steegmann, Juan
    Colomer, Dolors
    Gomez-Casares, Maria-Teresa
    Garcia-Gutierrez, Valentin
    Orti, Guillermo
    Ramirez-Payer, Angel
    Olavarria, Eduardo
    Vall-llovera, Ferran
    Giraldo, Pilar
    Conde, Eulogio
    Vallansot, Rolando
    Luis Lopez-Lorenzo, Jose
    Palomera, Luis
    Alvarez-Larran, Alberto
    Conesa, Venancio
    Bautista, Guiomar
    Casas, Laura
    Giles, Frank
    Hochhaus, Andreas
    Felipe Casado-Montero, Luis
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (10) : 2059 - 2066
  • [39] Incidence of hyperlipidemia among patients with chronic myelogenous leukemia (CML) receiving first or second line therapy with dasatinib or nilotinib
    Franklin, Meg
    Burns, Leah
    Perez, Samuel
    Yerragolam, Deepak
    Makenbaeva, Dinara
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
    Juan Luis Steegmann
    Dolors Colomer
    Maria-Teresa Gómez-Casares
    Valentín García-Gutiérrez
    Guillermo Ortí
    Angel Ramírez-Payer
    Eduardo Olavarria
    Ferrán Vall-llovera
    Pilar Giraldo
    Eulogio Conde
    Rolando Vallansot
    Jose Luis López-Lorenzo
    Luis Palomera
    Alberto Álvarez-Larrán
    Venancio Conesa
    Guiomar Bautista
    Laura Casas
    Frank Giles
    Andreas Hochhaus
    Luis Felipe Casado-Montero
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 2059 - 2066
12345